Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

the years ended December 31, 2012 and 2011, the increase in fair value of the Symphony Icon purchase liability was $9.9 million and $6.8 million, respectively.

General and Administrative Expenses:  General and administrative expenses for the three months ended December 31, 2012 decreased two percent to $3.9 million from $4.0 million for the corresponding period in 2011. For the year ended December 31, 2012, general and administrative expenses decreased two percent to $17.0 million from $17.4 million for the corresponding period in 2011.

Consolidated Net Loss:  Net loss for the three months ended December 31, 2012 was $24.9 million, or $0.05 per share, compared to a net loss of $33.8 million, or $0.10 per share, in the corresponding period in 2011. Net loss for the year ended December 31, 2012 was $110.2 million, or $0.23 per share, compared to a net loss of $116.2 million, or $0.34 per share, for the corresponding period in 2011. For the three months and year ended December 31, 2012, net loss included non-cash, stock-based compensation expense of $1.6 million and $6.5 million, respectively. For the three months and year ended December 31, 2011, net loss included non-cash, stock-based compensation expense of $1.4 million and $5.7 million, respectively.

Cash and Investments:  As of December 31, 2012, Lexicon had $223.2 million in cash and investments, as compared to cash and investments of $206.8 million as of September 30, 2012 and $281.7 million as of December 31, 2011.

Lexicon Conference Call
Lexicon management will hold a conference call to discuss its clinical development progress and financial results for 2012 and financial guidance for 2013 at 11:00 a.m. Eastern Time on February 21, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 12316846. Investors can access a live webcast of the
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon To Present At The BIO CEO & Investor Conference
2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Lexicon to Provide Third Quarter 2012 Financial Results
5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
9. Lexicon to Provide Second Quarter 2012 Financial Results
10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Mass. , July 31, 2014  A ... members—who make decisions about which therapies are included ... formulary placement, according to a new Manhattan Research ... 2014 . The study finds that P&T committee ... pharmacy benefits managers (PBMs) have set a high ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
(Date:7/31/2014)... 31, 2014 For its innovative modular Biomedical ... , Art,s-Way Scientific has earned a Modular Building Institute ... in over 30 categories, MBI,s contest is the commercial ... include building manufacturers, dealers, and product and service providers. ... the capability of our team," said Dan Palmer ...
Breaking Medicine Technology:Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Lazarus Effect Closes $5 Million Financing 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that ... viewing. LINK: www.retailinvestorconferences.com > Click the ... Pharmaceuticals, presentation will be available for 90 days. Investors ... for the next three weeks. About ...
... June 6, 2011 Express Scripts, Inc. (Nasdaq: ... Blair 2011 Growth Stock Conference on June 16, 2011 at ... Hotel in Chicago. This presentation will also ... the investor relations section of Express Scripts web site at ...
Cached Medicine Technology:Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:7/31/2014)... of invasive lionfish causing fish poisoning may be unfounded. ... derbies and targeted fisheries may remain the best way ... to know for sure whether a lionfish is toxic: ... lionfish were first reported off the coast of Florida ... number ever since. They,re now found in marine habitats ...
(Date:7/31/2014)... Bedford Commons OB-GYN partnered with ... ReEnergizers to do what Christina Haag, the practice ... the community all while still offering the greatest service ... to women’s health needs for every stage of their ... care ( Gynecology ), worked diligently with their marketing ...
(Date:7/31/2014)... 31, 2014 Today, Good Neighbor ... enhance patient care by kicking off another year ... The first of many education sessions and initiatives ... 2014, Good Neighbor Pharmacy and AmerisourceBergen’s annual conference. ... Services (CMS) Star Measures were a highlight and ...
(Date:7/31/2014)... 2014 Ticket Down is a ... Dick’s Sporting Goods Park in suburban Denver on Tuesday, ... soccer team has found a second home competing on American ... time playing international friendly games and will look to have ... Goods Park in Commerce City, Colorado. The match will be ...
(Date:7/31/2014)... HealthDay Reporter , THURSDAY, July 31, ... food, TVs or cigarettes, but people of ancient times commonly ... speculates on some reasons why. Using CT scans of ... the American Southwest, researchers have found evidence of widespread atherosclerosis ... build up, eventually leading to heart attack or stroke. ...
Breaking Medicine News(10 mins):Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 2Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 4Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 2Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 3
... drug prolonged progression-free survival, study finds , , SATURDAY, ... Avastin to chemotherapy lengthened progression-free survival in women ... Previous studies have found that adding Avastin (bevacizumab) ... with advanced breast cancer actually doubled progression-free survival. ...
... Anti-angiogenesis drug prolonged progression-free survival, study finds , , ... drug Avastin to chemotherapy lengthened progression-free survival in ... , Previous studies have found that adding Avastin ... women with advanced breast cancer actually doubled progression-free ...
... Phase II studies demonstrated potential for pazopanib as a single,agent treatment for ... -- In patients with stage I-III non-small cell lung cancer, 86 ... experienced a reduction in tumor volume ... overall response rate of 35 percent. The ...
... AIDS Walk, Run and Wellness Festival with ... at 9:30 a.m., Walk at 10 a.m., BOSTON, May 31 ... weekend, took a break from her rehearsal,on Friday night to meet ... Walk Boston., (Photo: http://www.newscom.com/cgi-bin/prnh/20080531/CLSA004 ), The 23rd ...
... , A study by Indiana University researchers found ... elderly study participants and their postural stability -- or ... with recent findings by other researchers involving the brain ... probe cognitive function effective at identifying people with poorer ...
... manufacturing, unreliable delivery of the drug , , FRIDAY, May ... drug rotigotine help relieve restless legs syndrome (RLS), according ... -- which stimulate the body,s dopamine system -- are ... rotigotine is already used to treat Parkinson,s disease. This ...
Cached Medicine News:Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:Sunday's AIDS Walk Boston at the Esplanade Gets Tribute from Cyndi Lauper at True Colors Concert Tour Launch Rehearsal 2Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Rotigotine Skin Patch May Ease Restless Legs Symptoms 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: